Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.
Young PA, Márquez-Garbán DC, Noor ZS, Moatamed N, Elashoff D, Grogan T, Romero T, Sasano H, Saito R, Rausch R, Hamilton N, Dubinett SM, Garon EB, Pietras RJ. Young PA, et al. Among authors: elashoff d. JTO Clin Res Rep. 2021 Feb 3;2(4):100150. doi: 10.1016/j.jtocrr.2021.100150. eCollection 2021 Apr. JTO Clin Res Rep. 2021. PMID: 34590007 Free PMC article.
Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.
Sun N, Lee YT, Zhang RY, Kao R, Teng PC, Yang Y, Yang P, Wang JJ, Smalley M, Chen PJ, Kim M, Chou SJ, Bao L, Wang J, Zhang X, Qi D, Palomique J, Nissen N, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Markovic D, Elashoff D, Yu HH, Li H, Heaney AP, Posadas E, You S, Yang JD, Pei R, Agopian VG, Tseng HR, Zhu Y. Sun N, et al. Among authors: elashoff d. Nat Commun. 2020 Sep 7;11(1):4489. doi: 10.1038/s41467-020-18311-0. Nat Commun. 2020. PMID: 32895384 Free PMC article.
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Garon EB, et al. Among authors: elashoff d. Mol Cancer Ther. 2010 Jul;9(7):1985-94. doi: 10.1158/1535-7163.MCT-10-0037. Epub 2010 Jun 29. Mol Cancer Ther. 2010. PMID: 20587667 Free PMC article.
Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S. Srivastava MK, et al. Among authors: elashoff d. PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677. Epub 2012 Jul 16. PLoS One. 2012. PMID: 22815789 Free PMC article.
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Garon EB, et al. Among authors: elashoff rm, elashoff d. Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016/j.lungcan.2018.06.013. Epub 2018 Jun 22. Lung Cancer. 2018. PMID: 30089602 Free PMC article. Clinical Trial.
Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.
Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, Wallace WD, Magyar CE, Grogan TR, Elashoff D, Walser T, Yanagawa J, Aberle DR, Barrio JR, Dubinett SM, Shackelford DB. Scafoglio CR, et al. Among authors: elashoff d. Sci Transl Med. 2018 Nov 14;10(467):eaat5933. doi: 10.1126/scitranslmed.aat5933. Sci Transl Med. 2018. PMID: 30429355 Free PMC article.
474 results